Tuesday, August 29, 2017

ARMO BioSciences Adds $67M For Cancer Treatments

Redwood City-based ARMO Biosciences, a developer of cancer treatments, said today that it has raised $67 in a Series C-1 funding. The funding was led by Qiming Venture Partners, and also included Decheng Capital, Sequoia Capital, Quan Capital, RTW Investments plus Kleiner Perkins (KP), OrbiMed, DAG Ventures, NanoDimension, HBM Healthcare Investments, GV (formerly Google Ventures), Celgene Corporation, and certain private investment funds advised by Clough Capital Partners L.P. The company said the funding goes towards Phase 2/3 studies on its lead compound, aimed at treating non-small cell lung cancer and renal cell cancer and to support an ongoing pivotal phase 3 clinical trial in advanced pancreatic cancer. More information »